$VIVE Viveve Medical Inc Has Gaps To Fill

17 giu 2019

VIVE has come across our screen after the company received 510k approval of its Viveve System 2.0, which is its second generation product. This is a big development and explains why the stock is up 24% today.

We believe there's a lot more room for VIVE to run as there are gaps above that need to be filled. There's $1.50 to $1.84 and then $2.50 to $3.18

Furthermore, the risk/reward looks good. Can go Long here with a stop at new 52-week lows at $.41 a share.

As always, trade with caution and use protective stops.

Good luck to all!

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.

Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two trials, if successful, could support marketing applications in the U.S. and over 30 countries around the world for this new commercial indication.

19 ago 2019

Trade chiuso: stop raggiunto

Stopped out on VIVE